This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%. The response was similar regardless of PD-L1 status, and response was related to
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung - Cancer
May 23, 2018
The author demonstrates a uniportal fissureless approach to resect the anterior segment of the right upper lobe, followed by lymph node dissection.
May 23, 2018
Using eight computed tomography radiographic features in an automated algorithm, differentiating between benign and malignant status of indeterminate pulmonary nodules had an area under the curve of 0.939.
May 19, 2018
This overview of some recent social science flavored research identifies challenges associated with stigma attached to a lung cancer diagnosis. These challenges include decreased participation in screening tests, noncompliance with therapy, and poor communication with treating physicians.
May 18, 2018
Patient Care
Three-dimensional heart models help patients and families understand congenital heart defects at a hospital in Seattle, Washington, USA.
May 14, 2018
The authors demonstrate a hybrid uniportal VATS left upper lobectomy with chest wall resection and reconstruction.
May 9, 2018
This video showed the feasibility of a robotic approach to perform a lobectomy with radical lymphadenectomy for locally advanced non-small cell lung cancer after induction chemotherapy.
May 1, 2018
This video demonstrates a robotic-assisted anatomic resection of the anterior segment.
April 30, 2018
This video demonstrates a robotic pulmonary parenchyma-sparing resection of a carcinoid tumor.